combinatory

Earlier this year, it commenced the recruitment of 220 patients for its combinatory Phase Ib clinical trial in triple negative breast cancer.

They challenge conventions and ask 'what can be?' Einstein called this a 'combinatory play'.

She argues that by utterly dissolving the distinction between text and image in the central pagoda, this combinatory composition projects a new new visual relationship between two previously distinct media.

Some research has found that TPM was able to inhibit the mitochondrial zinc enzyme carbonic anhydrase-V, resulting in tricarboxylic cycle dysfunction and severe lactic acidosis.[13],[14] However, in a pilocarpine model, TPM showed a neuroprotective effect.[15] The recommendations for the treatment of myoclonic seizures in mitochondrial diseases are controversial.[2],[10] Currently, it is considered less effective to use monotherapy, and a combinatory approach for myoclonic seizures treatment is recommended.

Accordingly the communication system can be safer whereby cooperative method [21], constellation scrambling method [22] and parallel combinatory method [23].

Such combinatory processes allow for surprises, for the unexpected, and for discoveries in children and individuals who have and hold a sense of toying or playing (Hockney, 1993, p.

This kind of combinatory calculation is a matrix for the action the artist carries out to arrange four different stones according to a principle of permutation (From One to Four Pebbles, 1972).

I am by no means the first scholar to identify a combinatory logic in Aurora Leigh, one that unites disparate pieces in order to do its political work.

It was reported yesterday that As a result of the deal, DanDrit owns a perpetual, fully paid up, royalty free, sub-licensable, exclusive, license to new technology platforms intended for the treatment of HIV, including combinatory gene therapy methods, and Enochian is now a wholly owned subsidiary of DanDrit.

In present review article, the characteristics of anti-PD-1/PD-L1 antibodies, biomarkers, and companion diagnostic assays for patient identification and the significance of the correlation between PD-1/PD-L1 signaling and other driver oncogenes (EGFR, ALK, KRAS, MET, ROS1) in a combinatory therapy including immune checkpoint blockades and targeted agents were also highlighted.

EU-ToxRisk is spearheading the development and evaluation of new tools and their combinatory power for regulatory risk assessment in Europe.